finacialnews-logo-final-01 (2).png
New Research Reveals Emergence of New Variants of Coronavirus to Boost COVID-19 Therapeutics Market Growth
04 sept. 2024 09h15 HE | FN Media Group LLC
PALM BEACH, Fla., Sept. 04, 2024 (GLOBE NEWSWIRE) -- FN Media Group News Commentary - The SARS-CoV-2, literally affected the whole world in these past years and has increased a global search for...
finacialnews-logo-final-01 (2).png
Global Coronavirus Therapeutics Market Size Projected to Exceed $16 Billion By the End of 2031
04 sept. 2024 08h30 HE | FN Media Group LLC
PALM BEACH, Fla., Sept. 04, 2024 (GLOBE NEWSWIRE) -- FN Media Group News Commentary - The emergence of SARS-CoV-2, which triggered the COVID-19 pandemic with overall is widely regarded as the...
190705_Biontech_Logo_RGB_Dark Green (Preferred)_0.png
Pfizer and BioNTech Receive U.S. FDA Approval & Authorization for Omicron KP.2-adapted COVID-19 Vaccine
22 août 2024 14h15 HE | BioNTech SE
The updated COVID-19 vaccine is tailored to the KP.2 strain of the SARS-CoV-2 Omicron JN.1 lineage and is recommended for individuals 6 months of age and olderThe KP.2 adaptation is based on FDA...
Pfizer und BioNTech
Pfizer und BioNTech geben Update zu mRNA-basiertem Kombinationsimpfstoffprogramm gegen Grippe und COVID-19 bei Personen im Alter von 18 bis 64 Jahren bekannt
16 août 2024 06h45 HE | BioNTech SE
Pfizers und BioNTechs Kombinationsimpfstoffkandidat gegen Grippe und COVID-19 hat in einer Phase-3-Studie eines ihrer beiden primären Ziele zur Immunogenität erreichtDie Studie erreichte eines ihrer...
Pfizer and BioNTech
Pfizer and BioNTech Provide Update on mRNA-based Combination Vaccine Program Against Influenza and COVID-19 in Individuals 18-64 Years of Age
16 août 2024 06h45 HE | BioNTech SE
 In a Phase 3 trial, Pfizer and BioNTech’s combination vaccine candidate against influenza and COVID-19 met one of its two primary immunogenicity objectivesThe trial did not meet one of its primary...
GeoVax.png
GeoVax Appoints Teresa Lambe, Acclaimed Professor of Vaccinology and Immunology at the Oxford Vaccine Group, to Its Scientific Advisory Board
08 août 2024 09h00 HE | GeoVax, Inc.
Strategic Appointment Enhances GeoVax’s Leadership and Expertise in Vaccine Development ATLANTA, GA, Aug. 08, 2024 (GLOBE NEWSWIRE) -- GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company...
Kronos-Logo-400px.jpg
Kronos Advanced Technologies Inc. Warns Consumers to Use Only FDA-Cleared Air Purifiers at Home and Office
16 juil. 2024 06h18 HE | Kronos Advanced Technologies Inc.
Los Angeles, CA , July 16, 2024 (GLOBE NEWSWIRE) -- Los Angeles, CA  July 16,  2024 (GLOBE NEWSWIRE) -- KRONOS ADVANCED TECHNOLOGIES, INC. (OTC MARKETS: KNOS) ("KNOS" or the "Company"), an...
Tevogen Logo Notified.png
Tevogen Bio Issues Letter to Stockholders Highlighting Recent Achievements, Growth Plans, and Consideration of a Potential Share Buyback
11 juil. 2024 12h21 HE | Tevogen Bio Inc
WARREN, N.J., July 11, 2024 (GLOBE NEWSWIRE) -- Tevogen Bio Holding Inc. (“Tevogen” or “Tevogen Bio”) (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech pioneer developing...
Pfizer und BioNTech
Pfizer und BioNTech erhalten positive CHMP-Empfehlung für an Omikron JN.1 angepassten COVID-19-Impfstoff in der Europäischen Union
27 juin 2024 10h30 HE | BioNTech SE
Der aktualisierte COVID-19-Impfstoff ist auf die Omikron JN.1-Sublinie von SARS-CoV-2 zugeschnitten und wird für Personen ab 6 Monaten empfohlenDie Beurteilung basiert auf präklinischen und...
Pfizer and BioNTech
Pfizer and BioNTech Receive Positive CHMP Opinion for Omicron JN.1-adapted COVID-19 Vaccine in the European Union  
27 juin 2024 10h30 HE | BioNTech SE
The updated COVID-19 vaccine is tailored to the Omicron JN.1 lineage of SARS-CoV-2 and is recommended for individuals 6 months of age and olderRecommendation is based on pre-clinical and...